---
title: "GeoVax Labs 10-K: Revenue $2.489M, Net Loss $(21.465) M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282893057.md"
description: "GeoVax Labs reported $2.489 million in revenue for the year, with a net loss of $(21.465) million, an improvement from the previous year. The operating loss was $(21.639) million, attributed to reduced R&D spending. The company is advancing its GEO-MVA program toward Phase 3 and has multiple Phase 2 trials for GEO-CM04S1. The Gedeptin cancer program has completed Phase 1/2 trials. GeoVax has raised capital through equity tranches to support its initiatives, with a cash runway extending into mid-Q2 2026."
datetime: "2026-04-15T20:05:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282893057.md)
  - [en](https://longbridge.com/en/news/282893057.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282893057.md)
---

# GeoVax Labs 10-K: Revenue $2.489M, Net Loss $(21.465) M

GeoVax Labs reported $2.489 million in revenue for the year, driven by a government contract that was terminated during the period, and reported a net loss of $(21.465) million (improved vs. prior year). Operating loss was $(21.639) million, reflecting lower R&D spending year-over-year, and cash used in operations totaled $(21.474) million, leaving runway into mid‑Q2 2026. The company has funded programs through multiple equity tranches and ATM proceeds while advancing clinical and manufacturing initiatives.

**Financial Highlights**

-   **Revenue:** $2.489 million (decline of $1.465 million vs 2024) — primarily from a government contract terminated during the year.
-   **Operating expenses (total):** $24.128 million (down $4.971 million vs 2024), reflecting reduced R&D spend.
-   **Loss from operations:** $(21.639) million (improvement of $3.505 million vs 2024).
-   **Net loss:** $(21.465) million (improvement of $3.528 million vs 2024).
-   **Net cash provided by (used in) operating activities:** $(21.474) million, primarily driven by the net loss and working capital changes.

**Business Highlights**

-   **GEO-MVA program:** Advancing toward Phase 3 with planned initiation in late 2026 following EMA advice to expedite development for mpox/smallpox vaccine indications.
-   **GEO-CM04S1 development:** Multiple Phase 2 trials underway, including studies in immunocompromised populations and booster trials, with promising interim immune responses reported.
-   **Gedeptin cancer program:** Completed Phase 1/2 in head and neck squamous cell carcinoma (HNSCC); Phase 2 combining intra-tumoral Gedeptin with pembrolizumab targeted for the first half of 2027.
-   **Manufacturing scale-up:** Developing a continuous avian cell line to enable scalable cGMP MVA vaccine production to address existing supply constraints.
-   **Operational funding actions:** Raised capital through multiple equity tranches and ATM proceeds to support clinical and manufacturing programs; current cash runway extends into mid‑Q2 2026.

Original SEC Filing: GeoVax Labs, Inc. \[ GOVX \] - 10-K - Apr. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GOVX.US](https://longbridge.com/en/quote/GOVX.US.md)
- [GOVXW.US](https://longbridge.com/en/quote/GOVXW.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats](https://longbridge.com/en/news/286807713.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)